Bryan Roberts

Bryan is a Partner at Venrock, joining the firm as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of health care investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Board of several other private companies, including Coderyte, Intarcia, Kyruus and Tandem Diagnostics. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking health care investor on Forbes’ Midas List since 2008. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.